Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) generates frequent news as it advances antibody-based therapies in immunology, with a particular emphasis on mast cell–driven diseases. Company updates often center on barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, and CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation.
News coverage for Celldex commonly includes clinical trial milestones across multiple indications. For barzolvolimab, the company reports data from Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticarias such as cold urticaria (ColdU) and symptomatic dermographism (SD), describing statistically significant improvements in urticaria activity scores, provocation tests and quality-of-life measures, along with favorable safety profiles. Investors and clinicians can also follow announcements about the global Phase 3 EMBARQ-CSU program in CSU and the registrational Phase 3 EMBARQ-ColdU and SD program in ColdU and SD.
Additional Celldex news items highlight expansion of the barzolvolimab program into prurigo nodularis and atopic dermatitis, as well as strategic decisions such as discontinuing development in eosinophilic esophagitis (EoE) after a Phase 2 study showed mast cell depletion without clinical benefit. Updates on CDX-622 provide insight into early-stage safety, pharmacokinetics and pharmacodynamics, including sustained reductions in serum tryptase in healthy volunteers.
Corporate news may feature quarterly financial results, leadership appointments and participation in healthcare and investor conferences. For readers tracking CLDX, this news stream offers a view into Celldex’s progress in mast cell biology, the evolution of its clinical pipeline and key regulatory and financial disclosures. Bookmarking this page allows ongoing access to company-issued press releases and related market-relevant developments.
Celldex Therapeutics (NASDAQ:CLDX) reported its financial results for Q4 and the full year 2022, showcasing notable advancements in its pipeline. The company highlighted positive data from its Phase 1b barzolvolimab study for chronic spontaneous urticaria (CSU), with significant symptom improvement rates reported. Phase 2 enrollment for CSU is expected to conclude by Q3 2023, with topline data anticipated late this year or early 2024. Celldex's financials show a net loss of $112.3 million for 2022, an increase from $70.5 million in 2021, primarily due to higher R&D expenses. The company maintains sufficient funds to support operations through 2025.
Celldex Therapeutics (NASDAQ:CLDX) presented promising Phase 1b clinical trial data for barzolvolimab, aimed at treating patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. At week 12, 56% of patients on multiple doses achieved complete response, while 76% showed well-controlled disease. After 24 weeks, 53% maintained complete response. The drug exhibited a favorable safety profile, with most adverse events being mild or moderate. Barzolvolimab demonstrates potential as a best-in-class therapy in the limited treatment landscape for CSU, paving the way for ongoing Phase 2 trials.
Celldex Therapeutics (NASDAQ:CLDX) has appointed Dr. Rita Jain to its Board of Directors. Dr. Jain brings extensive experience in drug development, previously serving in executive roles at ChemoCentryx, Immunovant, and Akebia. According to CEO Anthony Marucci, her expertise will enhance the board's capabilities as the company advances its programs, particularly barzolvolimab, which aims to address various conditions in allergy and immunology. Dr. Jain expressed her excitement about joining the company during this critical phase. Celldex focuses on developing antibody-based therapeutics for serious diseases with significant unmet medical needs.
Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 9:20 am ET. This event will be available via webcast on their Investors & Media page, with a replay accessible for 90 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating severe diseases, including various cancers and inflammatory conditions. Their pipeline highlights antibody-based therapeutics that engage the human immune system to enhance patient outcomes.
Celldex Therapeutics (NASDAQ:CLDX) announced the presentation of data from its Phase 1b multi-dose study of barzolvolimab for chronic spontaneous urticaria at the AAAAI Annual Meeting 2023, occurring from February 24-27 in San Antonio, Texas. The presentation is scheduled for February 26th, showcasing data through 24 weeks for cohorts receiving varying dosages (0.5, 1.5, 3.0, and 4.5 mg/kg). New data will be highlighted, with the company hosting a live webcast on the same day at 4:00 pm CT. This study represents a critical step in the development of treatments targeting inflammatory diseases.
Celldex Therapeutics (NASDAQ:CLDX) recently shared promising results from its Phase 1b clinical trial of barzolvolimab, targeting chronic inducible urticaria. In this trial, all 9 patients with cold urticaria treated with a 1.5 mg/kg dose achieved a 100% response rate. The company also confirmed durable mast cell suppression and response in patients from previous cohorts treated at 3.0 mg/kg over an extended follow-up period. These findings were presented at the GA²LEN Global Urticaria Forum, reinforcing barzolvolimab's potential as an effective therapy for severe mast cell-driven diseases.
Celldex Therapeutics has announced presentations from its barzolvolimab development program at the 6th GA²LEN Global Urticaria Forum in Berlin, December 7-8, 2022. Key highlights include data from the Phase 1b cold urticaria cohorts at 1.5 mg/kg and 3.0 mg/kg. The first day features an oral presentation on cold urticaria responses to barzolvolimab. The second day features a poster on mast cell suppression and an encore oral presentation on chronic spontaneous urticaria effectiveness. A webcast conference call is scheduled for December 6 at 8:00 a.m. ET.
Celldex Therapeutics (NASDAQ:CLDX) announced participation in several upcoming investor conferences in November 2022. Management will engage in fireside chats at the Guggenheim 4th Annual Immunology and Neurology Conference on November 14, at 2:10 PM ET, followed by the Jefferies London Healthcare Conference on November 16 at 4:45 AM ET. The final conference is the Evercore ISI 5th Annual HealthCONx Conference on November 30 at 4:45 PM ET. Webcasts will be accessible on the Celldex website, with replays available for 30 days.
Celldex Therapeutics reported third-quarter 2022 financial results, revealing a net loss of $26.8 million, or $0.57 per share. The company had $323.5 million in cash assets, a decrease from the previous quarter. Revenue for Q3 was $0.4 million, down from $0.7 million in the same period last year. Significant clinical advancements include the initiation of Phase 2 studies for barzolvolimab, with promising early data showing symptom improvements in chronic urticaria patients. The company expects ongoing data releases and has plans for new bispecific antibody trials in 2023.
Celldex Therapeutics (NASDAQ:CLDX) announced positive interim results from the Phase 1b study of barzolvolimab in chronic spontaneous urticaria, showing significant symptom relief. The Phase 2 studies for chronic urticaria have commenced. Financially, total revenue dropped to $0.2 million in Q2 2022, down from $3.5 million in Q2 2021. R&D expenses surged to $20.7 million, influenced by clinical trial costs, while G&A expenses increased due to higher legal costs. The net loss reached $36.0 million, or ($0.77) per share. Despite the losses, the company maintains sufficient cash to fund operations through 2025.